Intrathecal (IT) chemotherapy is a widely used treatment for hematologic tumors with central nervous system involvement. We describe a 50-year-old patient with Burkitt type acute lymphocytic leukemia who developed a neurotoxic myelopathy after IT chemotherapy with methotrexate (MTX) and cytarabine (Ara-C). This type of adverse event is rare, is usually unresponsive to pharmacologic treatment and can be potentially devastating for the patient. Although rehabilitation was effective in restoring functional independence, only partial neurological recovery was achieved. Proper classification of spinal cord injury and outcome measures are essential to assess prognosis and treatment outcome in these patients.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Download PDF 
Post
